Check out your Company Bowl for anonymous work chats.
BARDA and Dascena, Inc. partner to further advance machine learning software to predict early health deterioration in hospitalized COVID-19 patients
BARDA and Dascena, Inc. partner to further advance machine learning software to predict early health deterioration in hospitalized COVID-19 patients
OAKLAND, Calif. – April 6, 2021 – Dascena, Inc., a machine learning algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that Andrew Pucher has been appointed as Chief Financial Officer. Mr. Pucher brings extensive experience in capital markets, financing, and public company operations to Dascena. “As Dascena continues to grow, the strength of our team is of the utmost importance. We are thrilled to welcome Andrew to Dascena, whose combination of deep capital markets and operating experience will be key to supporting the commercialization of our predictive algorithms across multiple healthcare markets,” said Ritankar Das, Founder and Chief Executive Officer of Dascena.
Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the company’s GI Bleed Risk Alert System (Gibras). GibrasTM is a cloud-based software application that uses a machine learning algorithm to analyze patient electronic health record (EHR) data to aid in the early prediction of gastrointestinal bleeding (GIB) in adult patients in a hospital setting.
Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced it is expanding its leadership team with the C-suite appointments of Jim Wingrove, Ph.D., as Chief Scientific Officer and David H. Ledbetter, Ph.D., as Chief Clinical Officer. Jonathan Roberts has been awarded the title of Chief Growth Officer.
October 2, 2020 - Dascena Receives FDA EUA for COVID-19 Hemodynamic Instability and Respiratory Decompensation Prediction System
Dascena Receives FDA EUA for COVID-19 Hemodynamic Instability and Respiratory Decompensation Prediction System
April 30, 2020 Dascena Announces Closing of $50 Million Series B Financing to Support Advancement of Diagnostic Algorithm Development Engine to Inform Patient Care and Improve Outcomes
Dascena Announces Closing of $50 Million Series B Financing to Support Advancement of Diagnostic Algorithm Development Engine to Inform Patient Care and Improve Outcomes